علاج الورم الميلانيني عديم الميلانين في الورم الميلانيني الجلدي غير القابل للاستئصال أو النقيلي — النوع البري BRAF

References

• For patients with BRAF wild-type, unresectable and/or metastatic cutaneous melanoma, the following treatment options should be offered (in no particular order): nivolumab plus ipilimumab followed by nivolumab OR nivolumab plus relatlimab OR nivolumab OR pembrolizumab.
• After progression on anti–PD-1–based therapy, patients with unresectable and/or metastatic BRAF wild-type cutaneous melanoma may be offered ipilimumab or ipilimumab containing regimens.
• It should be noted that ipilimumab at 3 mg/kg once every 3 weeks for up to four doses has been approved by the US FDA in these patients on the basis of the trial by Hodi et al.
• In addition, ipilimumab-containing regimens could potentially include nivolumab plus ipilimumab in patients who have progressed on single-agent nivolumab or pembrolizumab.